Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
✉ Email this page to a colleague
Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
Docket | ⤷ Try a Trial | Date Filed | 2022-02-23 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
Jury Demand | None | Referred To | Jennifer L. Hall |
Patents | 7,579,473; 8,877,776 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited
Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2023-12-12 | 167 | Post Trial Brief | ’s ANDA Products infringe Exelixis’ U.S. Patent No. 7,579,473, which covers cabozantinib. D.I. 331 (Final…439 patent U.S. Patent No. 11,091,439 (JTX-001) ’440 patent U.S. Patent No. …015 patent U.S. Patent No. 11,098,015 (JTX-003) ’349 patent U.S. Patent No. … claim 3 of U.S. Patent No. 11,298,349 (“the ’349 patent”). The ’349 patent is directed to a …including claim 4 of U.S. Patent No. 11,091,439 (“the ’439 patent”), claim 3 of U.S. Patent No. 11,091,440 (“ | External link to document |
2024-01-23 | 175 | Post Trial Brief | ’473 patent U.S. Patent No. 7,579,473 (DTX-13) ’776 patent U.S. Patent No. 8,877,776…’439 patent U.S. Patent No. 11,091,439 (JTX-1) ’440 patent U.S. Patent No. 11,091,440…’015 patent U.S. Patent No. 11,098,015 (JTX-3) ’349 patent U.S. Patent No. 11,298,349… ’439 patent, ’440 patent, ’015 patent, and ’349 Patents-in-Suit …the ’440 patent and ’015 patent would have been patentably indistinct over the ’473 patent. | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |